Breast Cancer Research: Blocking Androgen Receptors to Overcome Treatment Resistance

Breast cancer remains a significant health challenge, with approximately 2,400 women in Kansas diagnosed each year. While many breast tumors rely on estrogen for growth and are initially responsive to treatments like tamoxifen or aromatase inhibitors, a substantial portion—around a third of patients—eventually develop resistance. Emerging research at the University of Kansas Medical Center is shedding light on the mechanisms behind this resistance and exploring new therapeutic strategies.

The Role of Androgen Receptors in Treatment Resistance

Traditionally, breast cancer treatment has focused on blocking estrogen pathways. However, recent studies indicate that when tumors develop into resistant to these therapies, another hormone pathway—the androgen receptor—can step in to sustain cancer growth. This means that even after estrogen is blocked, the androgen receptor can continue to fuel the tumor.

New Therapies Targeting Androgen Receptors

Researchers at the University of Kansas Medical Center, led by graduate researcher Matt Konda, are actively working on developing a new therapy specifically designed to block the androgen receptor. This approach aims to address treatment resistance and improve outcomes for patients whose cancers have stopped responding to conventional hormone therapies. Konda’s research focuses on deepening our understanding of the mechanisms underlying tumor resistance and improving survival rates for those with treatment-resistant breast cancer.

The University of Kansas Cancer Center’s Approach

The University of Kansas Cancer Center provides multidisciplinary care, bringing together specialists such as surgical oncologists, medical oncologists, radiation oncologists, radiologists, and pathologists. This collaborative approach ensures comprehensive treatment plans tailored to each patient’s individual needs, considering other health conditions like heart disease or diabetes. The team meets weekly to discuss patient cases and align treatment strategies with national guidelines.

Future Directions and Clinical Trials

By uncovering the intricacies of resistance development and identifying new targets like the androgen receptor, researchers at KU hope to pave the way for innovative clinical trials and improved treatment options for breast cancer patients. This research has the potential to significantly impact the lives of those facing this challenging disease.

Learn more about the breast cancer care team at The University of Kansas Cancer Center.

Read more about Matt Konda’s research at KU Medical Center.